Paul Tudor Jones Clovis Oncology, Inc. Transaction History

Tudor Investment Corp Et Al

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $6,999 - $32,885	-11,110 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.43 - $3.14 $33,349 - $73,227	-23,321 Reduced 67.73%	11,110 $22,000
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.76 $92,963 - $163,891	34,431 New	34,431 $93,000
Q3 2021 Nov 15, 2021	SELL	$4.06 - $5.8 $1.34 Million - $1.92 Million	-331,063 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$5.02 - $7.05 $1.52 Million - $2.14 Million	303,196 Added 1088.01%	331,063 $1.92 Million
Q1 2021 May 17, 2021	BUY	$4.81 - $10.34 $134,040 - $288,144	27,867 New	27,867 $196,000
Q3 2020 Nov 16, 2020	SELL	$4.82 - $7.72 $57,521 - $92,130	-11,934 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$5.69 - $9.69 $67,904 - $115,640	11,934 New	11,934 $81,000
Q1 2020 May 15, 2020	SELL	$3.77 - $11.0 $251,210 - $732,974	-66,634 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$3.0 - $16.43 $199,902 - $1.09 Million	66,634 New	66,634 $695,000
Q3 2019 Nov 14, 2019	SELL	$3.93 - $15.35 $211,626 - $826,582	-53,849 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$12.81 - $25.67 $689,805 - $1.38 Million	53,849 New	53,849 $801,000
Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $294,104 - $397,380	-5,868 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$57.69 - $84.58 $338,524 - $496,315	5,868	5,868 $399,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.